Skip to contentpdufa.bio

BBP-418 FORTIFY (Phase 3)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

BBP-418 FORTIFY (Phase 3) is a BridgeBio Pharma, Inc. program in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Its next catalyst is a Readout in Q4 2028.

BBIO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Sponsor: BridgeBio Pharma, Inc. (BBIO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2028BBIO

Specialist biotech funds holding BBIO, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Cormorant Asset Management250,000$16.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is BBP-418 FORTIFY (Phase 3)'s next FDA decision or readout?

The next tracked catalyst for BBP-418 FORTIFY (Phase 3) is a Readout in Q4 2028.

What happened at BBP-418 FORTIFY (Phase 3)'s most recent FDA decision?

No FDA decision for BBP-418 FORTIFY (Phase 3) is in our archive yet.

What is BBP-418 FORTIFY (Phase 3) used for?

In our records BBP-418 FORTIFY (Phase 3) is under review or in development for Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Who makes BBP-418 FORTIFY (Phase 3)?

BridgeBio Pharma, Inc. (BBIO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.